Apixaban is a small-molecule, selective factor Xa inhibitor that inhibits both free and clot-bound factor Xa and has been approved for the clinical treatment of several thromboembolic diseases, including the prevention of VTE (Jiang et al., 2009). The gene discussed is F10; the disease is Thromboembolism.